The IDEAS Study Program, which includes the IDEAS Study and New IDEAS Study, is committed to providing investigators in academia and industry an opportunity to access data collected as part of the study for purposes that are consistent with the goals of the IDEAS Study program. This may include ancillary research studies, technology development and educational initiatives.
IDEAS Study data elements available for use will be viewable on the The Global Alzheimer’s Association Interactive Network (GAAIN) Platform. Explore Data. To request IDEAS Study data, please review and submit the Laboratory of Neuro Imaging (LONI) IDEAS Data Use Agreement.
Data Sharing and Publications Policy
The New IDEAS Data Sharing and Publications Policy provides information and guidelines for individuals and corporations wishing to request access to clinical, image and/or biosample data archived during the New IDEAS Study. The policy provides additional considerations, the request and approval process, and responsibilities regarding the use of data to provide reasonable access to the data. The policy will also allow the New IDEAS Study Team to meet its obligation of responsible data use and continue to pursue primary research aims documented in the study protocol.
Please review the New IDEAS Case Report Form (CRF) packet before submitting any data requests. This ensures accuracy and helps us process your request more efficiently.
Request New IDEAS Biosamples
The New IDEAS Research and Publications Committee is now accepting applications for requests to obtain blood samples obtained from patients who consented to participate in the New IDEAS biorepository. Patient eligibility criteria and the full study protocol can be found here.
Investigators developing genomic and plasma-based biomarkers of brain amyloidosis and Alzheimer's disease are encouraged to apply. The New IDEAS Biorepository will be used for validation, and not discovery studies, with the specific goal of advancing blood-based biomarkers as a first step in determining which patients should undergo amyloid PET scans in clinical practice.